Strikingly, tumors of mice treated with the G100–ACT combination had drastically lower percentage of CD8− CD4− cells (Fig. 4f), a population of cells that have been previously identified as “defective tumor-associated T cells,” whose presence is associated with tumor progression43. This evidence concerns the gene CD8A and neoplasm.